<DOC>
	<DOCNO>NCT00639158</DOCNO>
	<brief_summary>The primary purpose study compare safety efficacy ABT-335 ( investigational drug ) coadministered atorvastatin ezetimibe atorvastatin coadministered ezetimibe subject abnormal lipid ( fat ) level blood .</brief_summary>
	<brief_title>Safety Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin Ezetimibe Atorvastatin Coadministered With Ezetimibe Subjects With Multiple Abnormal Lipid ( Fat ) Levels Blood</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects mixed dyslipidemia ( trigylcerides , &gt; = 150 mg/dL &lt; 400 mg/dL ; HDLC &lt; 40 mg/dL male , &lt; 50 mg/dL female ; LDLC , &gt; = 130 mg/dL ) . Subjects must agree use adequate birth control method adhere American Heart Association ( AHA ) Diet . Subjects unstable uncontrolled medical condition consider inappropriate clinical trial . Subjects unstable dose medication receive Coumadin , oral , intravenous intramuscular cyclosporine , statin , certain medication . Women pregnant plan become pregnant , woman lactate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>